This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Sweeney, M. J. Articles by Clemens, J. A. Search for Related Content PubMed PubMed Citation Articles by Sweeney, M. J. Articles by Clemens, J. A.

Activity of 6-Methyl-8-substituted Ergolines against the 7,12-Dimethylbenz[a]anthracene-induced Mammary Carcinoma¹

The Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46206 [M. J. S., G. A. P., E. C. K., N. J. B., J. A. C.], and Greenfield Laboratories, Greenfield, Indiana 46140 [N. V. O.]

The ability of a series of 8ß-carboxamido ergolines, 8-formamido ergolines, and 8-methyl ergolines to cause regressions of established dimethylbenz[a]anthracene-induced mammary carcinomas was compared to some ergot alkaloids. Although most of the ergoline derivatives depressed serum prolactin concentrations in rats, only a few had pronounced effects against the dimethylbenz[a]anthracene-induced mammary carcinoma in rats. Some derivatives from each of the three groups of substituted ergolines gave comparable activities against the dimethylbenz[a]anthracene-induced mammary carcinoma.

¹ Presented in part at the 64th Annual Meeting of the American Association of Cancer Research, Atlantic City, April 11 to 13, 1973.

Received 7/ 1/74. Accepted 9/18/74.